Contraindications

Do not use the preparation:

- In patients with severe allergy symptoms or the presence of multiple severe allergies,
- In patients with a history of facial scarring or hypertrophic scarring,
- In patients with known hypersensitivity to any of the ingredients of the product, especially sodium hyaluronate,
- In patients with porphyria,
- In pregnant or lactating women,
- In young patients under 18 years of age,
- In patients with active (or) previous autoimmune disease.

Do not use if there is an active disease such as inflammation, infection or tumor at or near the treatment site.

Do not inject into the periorbital area (eyelids, dark circles, crow's feet) or forehead due to risk of ocular ischemia resulting in loss of vision.

]Do not inject intravascularly. Introduction of product into the vascular system may result in emboli, vascular occlusion, ischemia, or infarction,

Rare but serious adverse events associated with intravascular injection of soft tissue fillers into the face have been reported, including temporary or permanent visual impairment, blindness, cerebral ischemia, or cerebral hemorrhage resulting in stroke, skin necrosis, and damage to underlying facial structures,

Do not use in patients with:

- History of streptococcal disease (recurrent throat infections, acute rheumatic fever with or without cardiac involvement),

Patients taking substances that affect platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs or high-dose vitamin C, may experience increased bruising or bleeding at the injection sites, as with any injection.

ADVERSE EFFECTS

Patients must be informed of the potential risks and adverse events associated with the injection procedure and the use of this product.
Mild bleeding may occur during injection and disappear immediately after injection is stopped.
Occasionally, one or more of the following reactions may occur immediately or as a delayed reaction (this list is not complete):
Reactions usually associated with injections, such as redness, erythema, swelling, or pain. These reactions may last for a week:

- Hematomas in the treated area,
- Swelling in the treated area,
- Sclerosis or nodules in the treated area,
- Spots or discoloration in the treated area,
- Weak effect or poor filling effect,
- Allergy to any of the ingredients of the product, especially sodium hyaluronate.

Cases of necrosis, abscesses and granulomas have been described in the literature following sodium injections with hyaluronate.
However, these rare potential risks should be considered.
Patients should be advised to report any adverse effects that last longer:
More than one week to their physician.
The physician may then prescribe appropriate treatment for the patient,
Any other adverse reactions associated with injection of the product should be reported to the distributor and/or manufacturer.
Patients must be informed of the indications prior to treatment.
Treatment must be administered under appropriate aseptic conditions.